| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Bryszewska, Maria
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (22/22 displayed)
- 2024Recent advances in multifunctional dendrimer‐based complexes for cancer treatmentcitations
- 2023Ruthenium metallodendrimer against triple-negative breast cancer in micecitations
- 2023Boron nitride embedded in chitosan hydrogel as a hydrophobic, promising metal-free, sustainable antibacterial materialcitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Modelscitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary studycitations
- 2022Heterofunctionalized polyphenolic dendrimers decorated with caffeic acid: Synthesis, characterization and antioxidant activitycitations
- 2021Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNAcitations
- 2020Copper (II) metallodendrimers combined with pro- apaoptotic siRNAs as a promising strategy against breast cancer cellscitations
- 2020Glucose-modified carbosilane dendrimers: Interaction with model membranes and human serum albumincitations
- 2019Immunoreactivity changes of human serum albumin and alpha-1-microglobulin induced by their interaction with dendrimerscitations
- 2019Dendrimers and hyperbranched structures for biomedical applicationscitations
- 2019Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drugcitations
- 2019Dendrimer for Templating the Growth of Porous Catechol-Coordinated Titanium Dioxide Frameworks: Toward Hemocompatible Nanomaterialscitations
- 2018Ruthenium dendrimers as carriers for anticancer siRNAcitations
- 2016Fourier transform infrared spectroscopy (FTIR) characterization of the interaction of anti-cancer photosensitizers with dendrimerscitations
- 2015Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological actioncitations
- 2013Dendrimers as Antiamyloidogenic Agents. Dendrimer-amyloid Aggregates Morphology and Cell Toxicitycitations
- 2013Characterization of Dendrimers and Their Interactions with Biomolecules for Medical use by Means of Electron Magnetic Resonancecitations
- 2013Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applicationscitations
Places of action
| Organizations | Location | People |
|---|
article
Dendrimers and hyperbranched structures for biomedical applications
Abstract
The use of nanotechnology in biology and medicine has been marked by rapid progress of these industries due to the emergence of new devices, supramolecular systems, structures, complexes and composites. One striking example of nanotech polymers is dendrimers. Their structure is formed by branches of monomeric subunits diverging in all directions from the central core. In choosing monomers and functional groups in synthesis, one can precisely set the properties of the resulting macromolecules. Currently, with modifications, >100 types of dendrimers have been synthesized. Of these, the 5 most common families can be distinguished: (i) Polyamidoamine (PAMAM) dendrimers are based on the ethylenediamine core and their branches are constructed from methyl acrylate and ethylene diamine. Currently, there is a large selection of PAMAM dendrimers with surface groups of many types. (ii) Polypropyleneimine (PPI) dendrimers are based on a butylenediamine core and polypropyleneimine monomers. In addition to PPI, the second popular abbreviation of these dendrimers is DAB (diaminobutyl) – from the name of the nucleus. Currently commercially available are (iii) Phosphorus dendrimers. In phosphorus dendrimers, phosphorus atoms are present in the core and branches of the dendrimer. (iv) Carbosilane dendrimers are based on a silicon core and have ammonium or amino groups on the periphery. (v) Poly(lysine) and poly(L-ornithine) dendrimers are a dendrimeric structure composed of amino acids residues. Characteristic surface groups possessing hydrophobic or hydrophilic components help to encapsulate the ligands inside or attach them to the surface, ensuring protection from degradation. Drug molecules complexed with dendrimer can be delivered to target cell where they are released from the complex. Dendrimers can improve the bioavailability of drugs by increasing their solubility in water, and changing surface charge, thereby reducing toxicity. In this review, the properties of dendrimers as drug carriers are discussed.